Pharmaceutical company Eli Lilly has issued a warning about potential supply shortages for its popular diabetes and weight-loss drug, Mounjaro, in Canada. The surge in demand comes after Health Canada approved the medication for obesity treatment, leading to unprecedented prescription rates.
Why Is Mounjaro in High Demand?
Mounjaro, known generically as tirzepatide, has gained significant attention for its dual benefits in managing type 2 diabetes and aiding weight loss. Similar to Novo Nordisk's Wegovy, Mounjaro works by mimicking gut hormones that regulate blood sugar and appetite. Clinical trials have shown it can help patients lose up to 20% of their body weight.
Supply Chain Struggles
Eli Lilly acknowledged that while it is working to ramp up production, the overwhelming demand has strained supply chains. The company stated, "We are prioritising available doses for existing patients while managing new prescriptions to ensure continuity of care."
Impact on Patients
Healthcare providers in Canada are being advised to monitor prescriptions carefully to prevent stockouts. Dr. Sarah Jenkins, an endocrinologist, noted, "Patients relying on Mounjaro for diabetes management may face disruptions if supply issues persist."
Meanwhile, experts suggest that alternative treatments, such as Wegovy, could see increased use if Mounjaro remains scarce.
